'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.

@article{Rikhof2012BiginsulinlikeGF,
  title={'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.},
  author={Bart Rikhof and Winette T. A. van der Graaf and Albert J Suurmeijer and Jaap van Doorn and Gert Jan Meersma and Patricia J. T. A. Groenen and Ed Schuuring and Coby Meijer and Steven de Jong},
  journal={The American journal of pathology},
  year={2012},
  volume={181 1},
  pages={303-12}
}
New treatment targets need to be identified in gastrointestinal stromal tumors (GISTs) to extend the treatment options for patients experiencing failure with small-molecule tyrosine kinase inhibitors, such as imatinib. Insulin-like growth factor (IGF)-II acts as an autocrine factor in several tumor types by binding to IGF receptor type 1 (IGF-1R) and/or the insulin receptor (IR) isoform A. The aim of the present study was to investigate the putative role of unprocessed pro-IGF-II, called 'big… CONTINUE READING